Skip to content
AnalystLens

Elevance Health 8-K Report, Regulation FD Disclosure (Nov 10, 2026)

Reports
Regulation FD
Filing Date
Filed November 10, 2026
Period End
November 10, 2026
Security
ELV
In the record · 2016–202610-K1110-Q348-K134

ELV filed 11 annual reports (10-K), 34 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Deal closed8-K · Apr ’22Apr ’22
  3. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed November 10, 2026. Cited figures are marked; the original filing is the authoritative source.

Elevance Health, Inc. (ELV) has released an 8-K filing on November 10, 2026, primarily to reaffirm its full-year 2026 financial guidance to investors and analysts.

The company expects shareholders' earnings to be at least $22.00a per diluted share. This figure includes approximately $7.00 per diluted share attributable to net unfavorable items. Excluding these specific items, Elevance Health projects adjusted shareholders' earnings to be at least $29.00 per diluted share, a projection that does not incorporate further adjustments beyond those already accounted for in the third quarter of 2026.

Furthermore, the company reaffirmed its guidance for the full-year 2026 benefit expense ratio, which is expected to be 90.2%b, with a tolerance of plus or minus 50 basis points. This communication is intended to provide clarity and reinforce the company's financial outlook to the investment community amidst ongoing discussions.

Key Highlights

  1. Reaffirms full-year 2026 shareholders' earnings guidance of at least $22.00 per diluted share.
  2. Includes approximately $7.00 per diluted share of net unfavorable items in the guidance.
  3. Expects adjusted shareholders' earnings to be at least $29.00 per diluted share, excluding net unfavorable items.
  4. Adjusted earnings guidance does not include additional adjustments beyond Q3 2026 reported items.
  5. Reaffirms full-year 2026 benefit expense ratio guidance of 90.2% +/- 50 basis points.
  6. Information provided under Regulation FD Disclosure.

Frequently Asked Questions

  1. What is the primary purpose of this 8-K filing?

    The primary purpose of this 8-K filing is to reaffirm Elevance Health's financial guidance for the full year 2026 to investors and analysts during upcoming meetings. It covers both reported earnings per share and adjusted earnings per share, as well as the benefit expense ratio.

  2. What is Elevance Health's updated earnings per share (EPS) guidance for 2026?

    Elevance Health expects its shareholders' earnings to be at least $22.00 per diluted share for the full year 2026. This includes approximately $7.00 per diluted share of net unfavorable items. Excluding these unfavorable items, the company anticipates adjusted shareholders' earnings to be at least $29.00 per diluted share.

  3. What is the guidance for the benefit expense ratio in 2026?

    The company reaffirmed its guidance for the full year 2026 benefit expense ratio to be 90.2%, with a flexibility of plus or minus 50 basis points.

  4. Does the adjusted earnings guidance include any new or unexpected items?

    No, the adjusted shareholders' earnings guidance of at least $29.00 per diluted share does not include any other adjustment items beyond those already reported in the company's third quarter 2026 earnings.